Assistance Publique Hôpitaux de Paris - CHU Henri Mondor
Créteil, 94 010, France
NCT Number: NCT04386759
Introduction: The SARS-Cov-2 outbreak in France and the concomitant massive increase in the number of cases requiring hospital management create a major risk of COVID-19 infection for hospital staff. In addition to nosocomial transmission, the health care workers (HCWs), defined as persons serving in health care settings who have the potential for direct or indirect exposure to patients or infectious materials, are also exposed to community transmission. Whether HCWs acquire infection at work or in the community is important to adapt protection measures. A few studies investigated COVID-19 infection among medical and nursing personnel. However, none have analyzed all categories of hospital staff. As of April 9, 2020, a total of 9,282 US HCWs with confirmed COVID-19 had been reported to CDC (US), however description of occupational activities was not available. Therefore, limited information is available about COVID-19 infection among HCWs.
Thus, the objectives of the sdudy are to estimate the incidence of symptomatic SARS-CoV-2 infection in HCWs in five university hospitals (including geriatric hospitals) of the great Paris area and to estimate both nosocomial and community risk factors.
Method: A prospective and retrospective cohort study that includes all hospital staff (including medical and nursing personnel, health care managers, laboratory, radiology, reception staffs, stretcher-bearers, etc.) working in different departments of five university hospitals (acute medical centers and geriatric hospitals) in the great Paris area (9 000 HCWs). Incidence of symptomatic SARS-CoV-2 infection will be estimated with its 95%CI. Individual and contextual risk factors will be analyzed using multilevel multivariate logistic regression modelling to account for clustering and confounding.
Conclusion This study should make it possible to better characterize SARS-Cov-2 contamination of HCWs and to estimate the share of nosocomial transmission.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Créteil, 94 010, France
Details for "Study design" section
Time perspective : Retrospective and prospective cohort study.
Up to protocol v2.0: Data from healthcare workers with COVID+ diagnostic at the time of inclusion will only be collected retrospectively. In contrast, data from healthcare workers free from infection will be collected prospectively.
From protocol v3.0: Recruitment of healthcare workers will be prospective. A retrospective collection of exposures during the 15 days preceding the RT-PCR or the antigenic test for COVID diagnosis will be performed.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
None. Only implementation of a cohort with data collection via individual self-questionnaires and administrative services for contextual data.
Time frame: Up to 3 months
The primary endpoint will be the occurrence of confirmed (RT-PCR or antigenic test or work stopping) SARS-CoV-2 infection.
Time frame: Up to 3 months maximum
Information collected by a self questionnaire and service datas
Time frame: Up to 3 months maximum
Risks factor are collected by a self questionnaire and service datas
Assistance Publique - Hôpitaux de Paris
Other
COVID-19 Infection in Healthcare Workers: a Cohort Study
Acronym: HOP-COVID
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05411562
COVID-19, Coronaviridae Infections
Montreal, Quebec, Canada
View Trial DetailsNCT04405934
COVID-19, Coronaviridae Infections
London, United Kingdom
View Trial DetailsNCT04819165
COVID-19, Coronaviridae Infections
San Martín, Buenos Aires, Argentina
View Trial DetailsNCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial Details